Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Graft function–adapted tacrolimus therapy after liver transplantation
2011-004944-23Phase 4Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in immunocompromise, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Proportion of patients with toxic or insufficient tacrolimus trough levels during days 1–14 post-transplant. Started Dec 2011; status: terminated.
02
Drugs
tacrolimus
03
Conditions
immunocompromise
Beyond the preview
Go deeper on 2011-004944-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004944-23.